ATCvet code: QG02AD90
Pharmacotherapeutic group
Cloprostenol sodium, a (racemic) analogue of prostaglandin F2α (PGF2α), is a very potent luteolytic agent. It causes functional and morphological regression of the corpus luteum (luteolysis) followed by return to oestrus and normal ovulation.
Furthermore, this group of substances has a contractile effect on the smooth muscles (uterus, gastro-intestinal tract, respiratory tract, vascular system).
The veterinary medicinal product does not demonstrate any androgenic, oestrogenic or anti progesterone activity and its effect on pregnancy is due to its luteolytic property.
Unlike other prostaglandin analogues, cloprostenol has no thromboxane A2 activity and does not cause platelet aggregation.
Pharmacokinetic Properties
Metabolism studies, using 15-14C-cloprostenol have been performed in pigs and cattle (by IM administration) to determine residue levels.
The kinetic studies indicate that the compound is rapidly absorbed from the site of injection, is metabolised then excreted in approximately equal proportion in urine and faeces. In cattle, less than 1% of the administered dose is eliminated via milk.The major route of metabolism appears to be β-oxidation to the tetranor or dinor acids of cloprostenol.
Peak values of radioactivity in blood were observed within 1 hour of a parenteral dose and declined with a t½ of between 1 – 3 hours depending on species.